2MW4991
/ Mabwell (Shanghai) Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 16, 2024
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
(PRNewswire)
- "Studies have found that integrin αvβ8 is highly expressed in various tumors, and blocking αvβ8 can completely inhibit the release of TGF-β. 2MW4991 can completely block the release of TGF-β mediated by αvβ8, showing strong anti-tumor activity in various pharmacodynamic models such as CT26 and EMT6, and significantly promotes immune cell infiltration in tumors, greatly increasing the sensitivity of immune-excluded tumors to PD1 inhibitors. 2MW4991 has a significant synergistic effect when used in combination with PD1. The studies conducted in non-primate models have shown that 2MW4991 has good safety and metabolic profiles."
Preclinical • Oncology • Solid Tumor
March 06, 2024
2MW4991, a novel ADCC-enhanced integrin αvβ8 blocker, exhibits high anti-tumor potency and was well tolerated in cynomolgus monkeys
(AACR 2024)
- "Integrin αvβ8 is a main activator of TGF-β1 in the TME and overexpressed in some cancer types. 2MW4991 demonstrated potent anti-tumor activity by unleashing the immune cells suppressed by TGF-β1 in TME and Fc-mediated immune functions. These compelling preclinical results support further evaluation of 2MW4991 in clinical trials."
IO biomarker • Clear Cell Renal Cell Carcinoma • Head and Neck Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • CD8 • TGFB1
March 12, 2024
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
(PRNewswire-Asia)
- "Mabwell...announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, USA, from April 5-10, 2024."
Preclinical • Oncology
1 to 3
Of
3
Go to page
1